Indivior (NASDAQ:INDV - Get Free Report) had its price objective reduced by analysts at Piper Sandler from $16.00 to $13.00 in a note issued to investors on Thursday, MarketBeat reports. The brokerage currently has an "overweight" rating on the stock. Piper Sandler's price objective points to a potential upside of 36.55% from the stock's previous close.
A number of other analysts have also recently issued reports on INDV. Rodman & Renshaw began coverage on Indivior in a report on Tuesday, January 28th. They set a "buy" rating and a $16.00 price objective on the stock. RODMAN&RENSHAW upgraded shares of Indivior to a "strong-buy" rating in a research report on Tuesday, January 28th.
Check Out Our Latest Research Report on Indivior
Indivior Price Performance
NASDAQ:INDV traded down $0.18 on Thursday, reaching $9.52. 2,173,994 shares of the company's stock were exchanged, compared to its average volume of 590,834. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of -27.20 and a beta of 0.82. The stock has a fifty day simple moving average of $10.91 and a 200-day simple moving average of $10.58. Indivior has a 52 week low of $7.33 and a 52 week high of $22.53.
Indivior (NASDAQ:INDV - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The company reported $0.32 EPS for the quarter, hitting the consensus estimate of $0.32. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. The company had revenue of $298.00 million during the quarter, compared to the consensus estimate of $262.35 million. As a group, sell-side analysts predict that Indivior will post 1.22 EPS for the current year.
Institutional Trading of Indivior
Several institutional investors and hedge funds have recently modified their holdings of the business. Deerfield Management Company L.P. Series C raised its stake in Indivior by 74.4% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 8,883,160 shares of the company's stock valued at $110,418,000 after purchasing an additional 3,790,518 shares in the last quarter. Iron Triangle Partners LP purchased a new stake in shares of Indivior during the 3rd quarter valued at $8,243,000. Claret Asset Management Corp bought a new stake in shares of Indivior during the 4th quarter worth $9,304,000. Krensavage Asset Management LLC purchased a new position in Indivior in the third quarter worth $6,843,000. Finally, CenterBook Partners LP increased its stake in Indivior by 105.5% in the fourth quarter. CenterBook Partners LP now owns 1,147,841 shares of the company's stock valued at $14,268,000 after acquiring an additional 589,158 shares during the last quarter. Hedge funds and other institutional investors own 60.33% of the company's stock.
Indivior Company Profile
(
Get Free Report)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Articles
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
